Loading
KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Hydrolyses semenogelin-1 thus leading to the liquefaction of the seminal coagulum.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 1.00, genetic association 0.74, clinical 0.61).
In plain words · KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Hydrolyses semenogelin-1 thus leading to the liquefaction of the seminal coagulum. Location: Secreted (UniProt).
No product in this corpus aims at KLK3 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KLK3: RNA tissue enriched (prostate 7,518 nTPM); high antibody staining in 1 normal tissue; highest cancer staining prostate cancer (8 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 2 specific cancer types at or above 0.5 (prostate cancer, prostate carcinoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KLK3 tissue; Open Targets ENSG00000142515 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Watt K.W.K. et al, Proc. Natl. Acad. Sci. U.S.A, 1986, "Human prostate-specific antigen: structural and functional similarity with serine proteases". Source.
Sources: HGNC HGNC:6364 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P07288 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000142515 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: prostate cancer 0.67 (GraphQL API, CC0))
Hydrolyses semenogelin-1 thus leading to the liquefaction of the seminal coagulum. Location: Secreted (UniProt). Locus 19q13.33 (HGNC).
RNA: tissue enriched (prostate 7,518 nTPM), detected in many normal tissues.
RNA cancer enriched: Prostate Adenocarcinoma 19,655 pTPM.
HPA KLK3 tissue · HPA KLK3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KLK3" OR ABSTRACT:"KLK3" OR TITLE:"kallikrein related peptidase 3" OR ABSTRACT:"kallikrein related peptidase 3" OR TITLE:"Prostate-specific antigen" OR ABSTRACT:"Prostate-specific antigen") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KLK3, not a curated reading list.
Shares Prostate cancer (KEGG map), Open Targets Platform, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.